Chemotherapy-associated hepatotoxicity and hepatic resection for metastatic colorectal cancer

Sam C. Wang; Michael I. D'Angelica

doi:10.1007/s11888-014-0218-5

Chemotherapy-associated hepatotoxicity and hepatic resection for metastatic colorectal cancer

Sam C. Wang, Michael I. D'Angelica

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Approximately 50 % of patients with colorectal cancer will develop liver metastases. Complete resection is associated with 50 % five-year overall survival and 20 % long-term cure. Use of preoperative chemotherapy for patients with resectable colorectal metastasis to the liver is controversial. Among the arguments against use of preoperative chemotherapy is the resulting hepatotoxicity, which may increase the risk of hepatectomy. In this review, we assess the liver-specific toxicity profiles of the most commonly used chemotherapy agents and how this toxicity affects perioperative outcomes. We also comment on the use of neoadjuvant chemotherapy for patients with resectable colorectal metastasis.

Original language	English (US)
Pages (from-to)	195-203
Number of pages	9
Journal	Current Colorectal Cancer Reports
Volume	10
Issue number	2
DOIs	https://doi.org/10.1007/s11888-014-0218-5
State	Published - Jun 2014

Keywords

5-FU
5-Fluorouracil
Bevacizumab
Cetuximab
Chemotherapy-associated hepatotoxicity
Chemotherapy-associated steatohepatitis
Colorectal liver metastasis
HAIP
Hepatic artery infusion pump
Irinotecan
Neoadjuvant therapy
Nodular regenerative hyperplasia
Oxaliplatin
Sinusoidal obstruction syndrome
Steatohepatitis
Steatosis

ASJC Scopus subject areas

Hepatology
Oncology
Gastroenterology

Access to Document

10.1007/s11888-014-0218-5

Cite this

@article{41be96a5abbb4ddfbd0380f7fbf2ab3e,

title = "Chemotherapy-associated hepatotoxicity and hepatic resection for metastatic colorectal cancer",

abstract = "Approximately 50 % of patients with colorectal cancer will develop liver metastases. Complete resection is associated with 50 % five-year overall survival and 20 % long-term cure. Use of preoperative chemotherapy for patients with resectable colorectal metastasis to the liver is controversial. Among the arguments against use of preoperative chemotherapy is the resulting hepatotoxicity, which may increase the risk of hepatectomy. In this review, we assess the liver-specific toxicity profiles of the most commonly used chemotherapy agents and how this toxicity affects perioperative outcomes. We also comment on the use of neoadjuvant chemotherapy for patients with resectable colorectal metastasis.",

keywords = "5-FU, 5-Fluorouracil, Bevacizumab, Cetuximab, Chemotherapy-associated hepatotoxicity, Chemotherapy-associated steatohepatitis, Colorectal liver metastasis, HAIP, Hepatic artery infusion pump, Irinotecan, Neoadjuvant therapy, Nodular regenerative hyperplasia, Oxaliplatin, Sinusoidal obstruction syndrome, Steatohepatitis, Steatosis",

author = "Wang, {Sam C.} and D'Angelica, {Michael I.}",

year = "2014",

month = jun,

doi = "10.1007/s11888-014-0218-5",

language = "English (US)",

volume = "10",

pages = "195--203",

journal = "Current Colorectal Cancer Reports",

issn = "1556-3790",

publisher = "Springer Science + Business Media",

number = "2",

}

TY - JOUR

T1 - Chemotherapy-associated hepatotoxicity and hepatic resection for metastatic colorectal cancer

AU - Wang, Sam C.

AU - D'Angelica, Michael I.

PY - 2014/6

Y1 - 2014/6

N2 - Approximately 50 % of patients with colorectal cancer will develop liver metastases. Complete resection is associated with 50 % five-year overall survival and 20 % long-term cure. Use of preoperative chemotherapy for patients with resectable colorectal metastasis to the liver is controversial. Among the arguments against use of preoperative chemotherapy is the resulting hepatotoxicity, which may increase the risk of hepatectomy. In this review, we assess the liver-specific toxicity profiles of the most commonly used chemotherapy agents and how this toxicity affects perioperative outcomes. We also comment on the use of neoadjuvant chemotherapy for patients with resectable colorectal metastasis.

AB - Approximately 50 % of patients with colorectal cancer will develop liver metastases. Complete resection is associated with 50 % five-year overall survival and 20 % long-term cure. Use of preoperative chemotherapy for patients with resectable colorectal metastasis to the liver is controversial. Among the arguments against use of preoperative chemotherapy is the resulting hepatotoxicity, which may increase the risk of hepatectomy. In this review, we assess the liver-specific toxicity profiles of the most commonly used chemotherapy agents and how this toxicity affects perioperative outcomes. We also comment on the use of neoadjuvant chemotherapy for patients with resectable colorectal metastasis.

KW - 5-FU

KW - 5-Fluorouracil

KW - Bevacizumab

KW - Cetuximab

KW - Chemotherapy-associated hepatotoxicity

KW - Chemotherapy-associated steatohepatitis

KW - Colorectal liver metastasis

KW - HAIP

KW - Hepatic artery infusion pump

KW - Irinotecan

KW - Neoadjuvant therapy

KW - Nodular regenerative hyperplasia

KW - Oxaliplatin

KW - Sinusoidal obstruction syndrome

KW - Steatohepatitis

KW - Steatosis

UR - http://www.scopus.com/inward/record.url?scp=84903696677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903696677&partnerID=8YFLogxK

U2 - 10.1007/s11888-014-0218-5

DO - 10.1007/s11888-014-0218-5

M3 - Article

AN - SCOPUS:84903696677

SN - 1556-3790

VL - 10

SP - 195

EP - 203

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

IS - 2

ER -

Chemotherapy-associated hepatotoxicity and hepatic resection for metastatic colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this